← ANALYST RATINGS · TIPRANKS
Maravai Lifesciences Holdings (MRVI): analyst forecast and price target
Analyst consensus
Moderate Buy4 Buy2 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $7.88, the highest $9.00, the lowest $6.50. The average is +16.0% from the last price of $6.79.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $6.50 → $7.50+15.4% | Hold | +10.5% | Reiterated | 16.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.00 → $7.50+7.1% | Hold | +10.5% | Reiterated | 16.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.00 → $7.50+7.1% | Hold | +10.5% | Reiterated | 16.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.50 → $7.50+15.4% | Hold | +10.5% | Reiterated | 16.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.00 → $7.50+7.1% | Hold | +10.5% | Reiterated | 16.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.00 → $7.50+7.1% | Hold | +10.5% | Reiterated | 16.10.26on TipRanks 03:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 → $6.50−13.3% | Hold | −4.3% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 → $7.00−12.5% | Hold | +3.1% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $7.00−12.5% | Hold | +3.1% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 → $6.50−13.3% | Hold | −4.3% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $7.50 → $7.00−6.7% | Hold | +3.1% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $7.50 → $7.00−6.7% | Hold | +3.1% | Reiterated | 14.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 → $8.00+6.7% | Hold | +17.8% | Reiterated | 12.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.50 → $8.00+6.7% | Hold | +17.8% | Reiterated | 12.10.26on TipRanks 03:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 → $7.50−6.2% | Hold | +10.5% | Reiterated | 10.10.26on TipRanks 03:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $7.50−6.2% | Hold | +10.5% | Reiterated | 10.10.26on TipRanks 03:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 → $7.50−6.2% | Hold | +10.5% | Reiterated | 08.10.26on TipRanks 03:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.00 → $7.50−6.2% | Hold | +10.5% | Reiterated | 08.10.26on TipRanks 03:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 → $7.50−6.2% | Hold | +10.5% | Reiterated | 08.10.26on TipRanks 03:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 → $7.50−6.2% | Hold | +10.5% | Reiterated | 08.10.26on TipRanks 03:05 | — | |
| Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% | TD Cowen | $9.00 | Buy | +32.5% | Initiated | 05.10.26on TipRanks 06:25 | +7.2%next day −8.4% · 5 days −17.6% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 | Hold | +17.8% | Reiterated | 29.09.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 | Hold | +17.8% | Reiterated | 29.09.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 | Hold | +17.8% | Reiterated | 29.09.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.00 | Hold | +17.8% | Reiterated | 29.09.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 | Hold | +17.8% | Reiterated | 29.09.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 | Hold | +17.8% | Reiterated | 29.09.26on TipRanks 05:06 | — | |
| Matt Hewitt★★★★★★★★★★#3011 · hits 47% · avg +4.1% | Craig-Hallum | — | Buy | — | Reiterated | 15.09.26on TipRanks Sep 16 08:09 | +3.4%next day −0.1% · 5 days +6.1% | ↗ |
| Unknown Analyst | UBS | $2.50 → $8.00+220.0% | Hold | +17.8% | Initiated | 08.09.26on TipRanks Sep 11 06:05 | −1.2%next day −2.9% · 5 days −3.2% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $8.00 | Buy | +17.8% | Reiterated | 11.08.26on TipRanks Aug 12 22:05 | −4.0%next day −0.8% · 5 days −0.8% | ↗ |
| Unknown Analyst | Wells Fargo | $5.50 → $6.50+18.2% | Buy | −4.3% | Reiterated | 07.08.26on TipRanks 13:05 | −0.9%next day −2.5% · 5 days −8.9% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Hold | — | Reiterated | 07.08.26on TipRanks 04:50 | −0.9%next day −2.5% · 5 days −8.9% | ↗ |
| Subbu Nambi★★★★★★★★★★#281 · hits 72% · avg +34.4% | Guggenheim | — | Hold | — | Reiterated | 11.05.26on TipRanks 08:10 | −2.5%next day −1.5% · 5 days −13.8% | ↗ |
| Justin Bowers★★★★★★★★★★#8679 · hits 47% · avg 0.0% | Deutsche Bank | $4.50 → $6.00+33.3% | Buy | −11.6% | Reiterated | 08.05.26on TipRanks 09:00 | +22.3%next day −2.5% · 5 days −14.6% | ↗ |
| Catherine Ramsey Schulte★★★★★★★★★★#864 · hits 53% · avg +11.2% | Robert W. Baird | $2.00 → $3.00+50.0% | Hold | −55.8% | Reiterated | 26.02.26on TipRanks 10:25 | +9.8%next day +0.5% · 5 days +4.5% | ↗ |
| Unknown Analyst | Jefferies | $5.00 | Buy | −26.4% | Reiterated | 26.02.26on TipRanks 10:25 | +9.8%next day +0.5% · 5 days +4.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Maravai Lifesciences Holdings
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $7.50 at a price of $7.66 (−2.1%); now: $7.88 at $6.79 (+16.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 5 | 5 | 3 | 2 | 3 | 4 |
| Hold | 2 | 2 | 2 | 1 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.06 (from $-0.08 to $-0.04). Last quarter: $-0.02.
Sales
Next quarter’s sales estimate — $44M (from $42M to $45M). Last quarter: $51M.
Best top-analyst consensus in the sector · Healthcare
About Maravai Lifesciences Holdings
- CEO: Bernd Brust
- Employees: 415
- 10770 Wateridge Circle, San Diego, CA, 92121, US
- www.maravai.com
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
Data from the stock’s TipRanks forecast page, read 114 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗